DE3634671A1 - Antirheumatic agents with reduced toxicity - Google Patents

Antirheumatic agents with reduced toxicity

Info

Publication number
DE3634671A1
DE3634671A1 DE19863634671 DE3634671A DE3634671A1 DE 3634671 A1 DE3634671 A1 DE 3634671A1 DE 19863634671 DE19863634671 DE 19863634671 DE 3634671 A DE3634671 A DE 3634671A DE 3634671 A1 DE3634671 A1 DE 3634671A1
Authority
DE
Germany
Prior art keywords
tryptophan
methionine
reduced toxicity
antirheumatic agents
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19863634671
Other languages
German (de)
Inventor
Hans Prof Dr Dr Kroeger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19863634671 priority Critical patent/DE3634671A1/en
Publication of DE3634671A1 publication Critical patent/DE3634671A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antirheumatic agents with reduced toxicity brought about by adding L-tryptophan and L-methionine are reported.

Description

Es ist allgemein bekannt, daß die Antirheumatika oft über lange Zeiträume eingenommen werden müssen. Sie entfalten dementsprechend auch unerwünschte Nebenwirkungen, die im Laufe der Zeit zu gefähr­ lichen chronischen Krankheitszuständen führen können. So sind Nebenwirkungen von dem viel verwendeten Aspirin bekannt, die lebensbedrohend sind. Auch treten gefahrvolle Nebenerscheinungen nach Dauereinnahme von Indomethacin, Penicillamin und von Gold­ präparaten, wie dem Auranofin u. a. auf.It is well known that the anti-inflammatory drugs are often long-lasting Periods must be taken. They unfold accordingly also undesirable side effects that become dangerous over time chronic chronic disease. So are Known side effects from the much used aspirin, the are life threatening. There are also dangerous side effects after continuous intake of indomethacin, penicillamine and gold preparations such as the Auranofin u. a. on.

Es sind zahlreiche Bemühungen unternommen worden, durch Änderung der Konstitution den chemischen Substanzen die unerwünschten Nebenwirkungen zu nehmen. Doch bisher waren alle Versuche wenig erfolgreich.Numerous efforts have been made through change the constitution of chemical substances undesirable To take side effects. So far, however, all attempts have been few successful.

Nun wurde die überraschende Beobachtung gemacht, daß die Amino­ säuren L-Methionin und L-Tryptophan, zusammen mit Antirheumatika verabreicht, einen sehr günstigen Einfluß auf die Eliminierung unerwünschter Nebenwirkungen besitzen. Zwar ist bei verschiedenen Leberleiden oft von einer protektiven Wirkung gewisser Amino­ säuren berichtet worden, so in OS-PS 20 13 026 von Leucin, Isoleucin, Lysin, Phenylalanin und/oder Tryptophan; aminosäurehaltige Infu­ sionslösungen sind zur Behandlung von schweren Leberinsuffizienzen vorgeschlagen worden (OS-PS 29 44 341).Now the surprising observation has been made that the amino acids L-methionine and L-tryptophan, along with anti-inflammatory drugs administered, a very favorable influence on the elimination have undesirable side effects. Although at different Liver disorders often have a protective effect of certain amino acids acids have been reported, for example in OS-PS 20 13 026 of leucine, isoleucine, Lysine, phenylalanine and / or tryptophan; amino acid infu Solutions are for the treatment of severe liver insufficiency have been proposed (OS-PS 29 44 341).

In Tabelle 1 ist der Einfluß verschiedener Antirheumatika auf die Leber aufgezeigt an Hand verschiedener Enzymaktivitäten. Allgemein ist es anerkannt, daß die Serum-Enzyme Glutamat-Oxylat- Transaminasen (GOT) und Glutamat-Pyroxal-Transaminase (GPT) bei Schädigung der Leber ansteigen. Von unserem Arbeitskreis wurde beobachtet, daß die Aktivität der Tyrosin-Aminotransferase (TAT) durch eine Reihe von Substanzen erhöht werden kann. Hierbei handelt es sich um das erste Enzym des Tyrosin-Abbaus.Table 1 shows the influence of various anti-inflammatory drugs the liver is shown using various enzyme activities. It is generally accepted that the serum enzymes glutamate oxylate Transaminases (GOT) and glutamate pyroxal transaminase (GPT) Liver damage increase. From our working group observed that the activity of tyrosine aminotransferase (TAT) can be increased by a number of substances. Here it is the first enzyme to break down tyrosine.

Im Verlaufe der Leberschädigung ist auch die Aktivität des Enzyms Adenosindiphosphatribose-Transferase (ADPR-Transferase) erhöht. Dieses Enzym überträgt unter Spaltung von NAD ADPR auf das Pro­ tein. Die Folge ist eine Konformations-Änderung des Proteins. Dadurch wird eine Regulation ermöglicht. The activity of the enzyme is also in the course of liver damage Adenosine diphosphatribose transferase (ADPR transferase) increased. This enzyme transfers ADPR to the Pro by cleaving NAD complexion. The result is a change in the conformation of the protein. This enables regulation.  

Eine deutliche Zunahme der Aktivitäten von GOT, GPT und TAT kann beobachtet werden bei der Gabe von Aspirin, Auranofin, Indomethacin und Diclofenac. Hierbei kommt es teilweise auch zu einer Zunahme der ADPR-Transferase-Aktivität. Gleichzeitige Gabe von Methionin und Tryptophan verhindert diese Zunahme beträchtlich.A significant increase in the activities of GOT, GPT and TAT can be observed when aspirin, auranofin, Indomethacin and diclofenac. This also happens in part to an increase in ADPR transferase activity. Simultaneously Administration of methionine and tryptophan prevents this increase considerably.

Unsere Versuchsanordnung zeigt:
L-Methionin und L-Tryptophan wurden zu gleichen Teilen miteinander gemischt und verrieben. Von dieser Metryphan genannten Mischung erhielten Ratten 600 mg/kg intraperitoneal verabreicht. Die antirheumatischen Substanzen wurden in den in Tabelle 1 angegebenen Dosen intraperitoneal zusammen mit dem Metryphan verabreicht. Die Tiere wurden nach drei Stunden getötet. Die GOT und GPT wurden nach H. U. Bergmeyer (Methoden der enzyma­ tischen Analyse Bd. I, S 492, Verlag Chemie, 1974), Tyrosin- Amino-Transferase (TAT) nach H. Kröger und Mitarb. (Biochem. Z. 341, 190, 1965) und ADPR-Transferase nach R. R. Kidwell und Mitarb. (Biochem. Biophys. Res. Commun. 61, 766, 1974) bestimmt. Dimethylsulfoxyd wurde 1 : 2 verdünnt mit 0,1 M NaCl; 0,15 M NaCl diente als Kontrolle. Tabelle 1 zeigt die Ergebnisse.
Our experimental setup shows:
L-methionine and L-tryptophan were mixed in equal parts and triturated. Rats received 600 mg / kg intraperitoneally from this mixture called Metryphan. The antirheumatic substances were administered intraperitoneally together with the metryphan in the doses indicated in Table 1. The animals were sacrificed after three hours. The GOT and GPT were according to HU Bergmeyer (methods of enzymatic analysis vol. I, S 492, Verlag Chemie, 1974), tyrosine amino transferase (TAT) according to H. Kröger and Mitarb. (Biochem. Z. 341, 190, 1965) and ADPR transferase according to RR Kidwell and Mitarb. (Biochem. Biophys. Res. Commun. 61, 766, 1974). Dimethyl sulfoxide was diluted 1: 2 with 0.1 M NaCl; 0.15 M NaCl served as a control. Table 1 shows the results.

Um welchen genaueren Mechanismus es sich bei dieser eindeutigen Wirkung handelt, und zwar bei der Vielzahl der Verschieden­ heit chemischer Konstitutionen, soll noch eine offene Frage bleiben.What more precise mechanism is this unique Effect acts, and that with the multitude of different of chemical constitutions should still be an open question stay.

Metryphan kann in Form von Tabletten, Kapseln, Dragees, Tropfen, Sirups und dergleichen direkt mit den antirheumatischen Körpern verabreicht werden oder auch gesondert.Metryphan can be in the form of tablets, capsules, coated tablets, drops, Syrups and the like directly with the anti-rheumatic bodies be administered or separately.

In Tabelle 2 aufgezeigte Beispiele sollen die Ausführung der Erfindung zeigen. Examples shown in Table 2 are intended to implement the Show invention.  

Tabelle 1 Table 1

Azetylsalicylsäure 400 mg L-Methionin 200 mg L-Tryptophan 200 mg Tablettenhilfsmittel, ad.1000 mg Acetylsalicylic acid 400 mg L-methionine 200 mg L-tryptophan 200 mg tablet excipients, ad.1000 mg

Tablettenherstellung in konventioneller Weise zu 1 g.Tablet production in a conventional manner at 1 g.

Beispiel 3Example 3 KapselnCapsules

Diclofenac-Natrium  25 mg L-Methionin 200 mg L-Tryptophan 200 mgDiclofenac sodium 25 mg L-methionine 200 mg L-tryptophan 200 mg

Die Bestandteile werden gemischt und in konventioneller Weise in Kapseln gefüllt.The ingredients are mixed and in a conventional manner filled in capsules.

Beispiel 4Example 4

Auranofin   3 mg L-Methionin 100 mg L-Tryptophan 100 mgAuranofin 3 mg L-methionine 100 mg L-tryptophan 100 mg

Bestandteile werden gemischt, granuliert nach konventioneller Art und in Kapseln gebracht.Ingredients are mixed, granulated in the conventional way and in Capsules brought.

Beispiel 5Example 5

Natriumgentiat  90 mg L-Methionin 150 mg L-Tryptophan 150 mgSodium gentiate 90 mg L-methionine 150 mg L-tryptophan 150 mg

werden in konventioneller Weise zu Dragees von 500 mg verarbeitetare processed in a conventional manner to 500 mg coated tablets

Beispiel 6Example 6

Indometacin  50 mg L-Methionin 100 mg L-Tryptophan 100 mgIndomethacin 50 mg L-methionine 100 mg L-tryptophan 100 mg

Kapseln nach konventioneller Art.Capsules the conventional way.

Beispiel 7Example 7

Ibuprofen 400 mg L-Methionin 200 mg L-Tryptophan 200 mgIbuprofen 400 mg L-methionine 200 mg L-tryptophan 200 mg

Kapseln nach konventioneller Art.Capsules the conventional way.

Claims (2)

1. Antirheumatika mit verminderter Toxizität, dadurch gekenn­ zeichnet, daß sie zusätzlich die Aminosäuren L-Methionin und L-Tryptophan enthalten.1. Anti- rheumatic drugs with reduced toxicity, characterized in that they additionally contain the amino acids L-methionine and L-tryptophan. 2. Antirheumatika nach Anspruch 1, dadurch gekennzeichnet, daß es die Aminosäuren in gleichen Gewichtsteilen ent­ hält. Dieser Anspruch stützt sich vor allem auf die Beispiele.2. Antirheumatics according to claim 1, characterized in that that it ent the amino acids in equal parts by weight holds. This claim is based above all on the examples.
DE19863634671 1986-10-09 1986-10-09 Antirheumatic agents with reduced toxicity Withdrawn DE3634671A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19863634671 DE3634671A1 (en) 1986-10-09 1986-10-09 Antirheumatic agents with reduced toxicity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863634671 DE3634671A1 (en) 1986-10-09 1986-10-09 Antirheumatic agents with reduced toxicity

Publications (1)

Publication Number Publication Date
DE3634671A1 true DE3634671A1 (en) 1988-05-19

Family

ID=6311533

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19863634671 Withdrawn DE3634671A1 (en) 1986-10-09 1986-10-09 Antirheumatic agents with reduced toxicity

Country Status (1)

Country Link
DE (1) DE3634671A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3912232A1 (en) * 1989-04-11 1989-11-30 Klosa Josef Remedy for urinary incontinence
EP1978408A1 (en) 2007-03-29 2008-10-08 FUJIFILM Corporation Negative resist composition and pattern forming method using the same
WO2009063824A1 (en) 2007-11-14 2009-05-22 Fujifilm Corporation Method of drying coating film and process for producing lithographic printing plate precursor
EP2105690A2 (en) 2008-03-26 2009-09-30 Fujifilm Corporation Method and apparatus for drying
WO2013015121A1 (en) 2011-07-27 2013-01-31 富士フイルム株式会社 Photosensitive composition, master plate for planographic printing plate, polyurethane, and method for producing polyurethane
WO2015064602A1 (en) 2013-10-31 2015-05-07 富士フイルム株式会社 Laminate, organic-semiconductor manufacturing kit, and resist composition for manufacturing organic semiconductor
US11848249B2 (en) 2019-09-26 2023-12-19 Fujifilm Corporation Manufacturing method for thermal conductive layer, manufacturing method for laminate, and manufacturing method for semiconductor device

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3912232A1 (en) * 1989-04-11 1989-11-30 Klosa Josef Remedy for urinary incontinence
EP1978408A1 (en) 2007-03-29 2008-10-08 FUJIFILM Corporation Negative resist composition and pattern forming method using the same
WO2009063824A1 (en) 2007-11-14 2009-05-22 Fujifilm Corporation Method of drying coating film and process for producing lithographic printing plate precursor
EP2105690A2 (en) 2008-03-26 2009-09-30 Fujifilm Corporation Method and apparatus for drying
WO2013015121A1 (en) 2011-07-27 2013-01-31 富士フイルム株式会社 Photosensitive composition, master plate for planographic printing plate, polyurethane, and method for producing polyurethane
WO2015064602A1 (en) 2013-10-31 2015-05-07 富士フイルム株式会社 Laminate, organic-semiconductor manufacturing kit, and resist composition for manufacturing organic semiconductor
US11848249B2 (en) 2019-09-26 2023-12-19 Fujifilm Corporation Manufacturing method for thermal conductive layer, manufacturing method for laminate, and manufacturing method for semiconductor device

Similar Documents

Publication Publication Date Title
EP0874618B1 (en) Preparation for improving hair growth, the skin structure and/or nail regeneration
Taghzouti et al. Alternation behavior, spatial discrimination, and reversal disturbances following 6-hydroxydopamine lesions in the nucleus accumbens of the rat
Otten et al. Selective induction of tyrosine hydroxylase and dopamine β-hydroxylase by nerve growth factor: comparison between adrenal medulla and sympathetic ganglia of adult and newborn rats
EP0210204B1 (en) Protein hydrolysates, production process and drugs containing th em
DE69933738T2 (en) Composition containing amino acids and trehalose
JPH02501065A (en) Methods and compositions for treating obesity, depression, drug abuse and narcolepsy
DE3206784A1 (en) AMINO ACID PREPARATIONS CONTAINING GLUTAMINE
DE3634671A1 (en) Antirheumatic agents with reduced toxicity
DE69935140T2 (en) USE OF ANABOLIKA, ANTI-CATABOLIC AGENTS, ANTIOXIDANTS AND ANALGETICS FOR THE PROTECTION, TREATMENT AND REPAIR OF BINDING WEBTS IN HUMANS AND ANIMALS
CH678918A5 (en)
EP0516594A1 (en) L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis
DE3223150C2 (en)
Morehead et al. Renal injury in the rat following the administration of serine by stomach tube
EP0714276B1 (en) Composition against hair loss and brittle nails
DE4211239C2 (en) Medicines for cardiovascular diseases
CA2283122A1 (en) Plant extract compositions, method of preparation, and pharmaceutical compositions containing them
WO1998008511A1 (en) Use of 2-phenyl-1, 2-benzisoselenazol-3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease
Tong et al. Role of cyclic GMP in the mediation of circadian rhythmicity of the adenylate cyclase-cyclic AMP-phosphodiesterase system in Euglena
DE69332947T2 (en) MEDICINAL PRODUCT CONTAINING 2- (3-BENZOYLPHENYL) -PROPIONIC ACID FOR USE AS AN ANALGETIC
DE69533742T2 (en) Use of proline and / or derivatives as anti-hepatitis agents
FR2511597A1 (en) PRODUCTS EXTRACTED FROM MARINE INVERTEBRATES, THEIR PREPARATION AND THEIR APPLICATIONS IN DIETETICS AND COSMETOLOGY
Reingold et al. INHIBITION OF BRAIN GLUTAMATE DECARBOXYLASE BY 2‐KETO‐4‐PENTENOIC ACID, A METABOLITE OF ALLYLGLYCINE 1
Imperato et al. Benzodiazepines prevent kainate-induced loss of GABAergic and cholinergic neurons in the chick retina
DE2803397A1 (en) BIOLOGICALLY ACTIVE SUBSTANCE, METHOD FOR THE PRODUCTION THEREOF AND MEANS CONTAINING THE SAME
King et al. Cocaine and amphetamine modification of cerebral energy metabolism in vivo

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee